IL-15 deficient Tax mice reveal a role for IL-1α in tumor immunity by Rauch, Daniel A et al.




IL-15 deficient Tax mice reveal a role for IL-1α in
tumor immunity
Daniel A. Rauch
Washington University School of Medicine in St. Louis
John C. Harding
Washington University School of Medicine in St. Louis
Lee Ratner
Washington University School of Medicine in St. Louis
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Rauch, Daniel A.; Harding, John C.; and Ratner, Lee, ,"IL-15 deficient Tax mice reveal a role for IL-1α in tumor immunity." PLoS
One.9,1. e85028. (2014).
http://digitalcommons.wustl.edu/open_access_pubs/2182
IL-15 Deficient Tax Mice Reveal a Role for IL-1a in Tumor
Immunity
Daniel A. Rauch, John C. Harding, Lee Ratner*
Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, Saint Louis, Missouri, United States of America
Abstract
IL-15 is recognized as a promising candidate for tumor immunotherapy and has been described as both a promoter of
cancer and a promoter of anti-cancer immunity. IL-15 was discovered in cells transformed by HTLV-1, the etiologic agent of
adult T cell leukemia/lymphoma (ATL) and the human retrovirus that carries the Tax oncogene. We have developed the
TAX-LUC mouse model of ATL in which Tax expression drives both malignant transformation and luciferase expression,
enabling non-invasive imaging of tumorigenesis in real time. To identify the role of IL-15 in spontaneous development of
lymphoma in vivo, an IL-152/2 TAX-LUC strain was developed and examined. The absence of IL-15 resulted in aggressive
tumor growth and accelerated mortality and demonstrated that IL-15 was not required for Tax-mediated lymphoma but
was essential for anti-tumor immunity. Further analysis revealed a unique transcriptional profile in tumor cells that arise in
the absence of IL-15 that included a significant increase in the expression of IL-1a and IL-1a-regulated cytokines. Moreover,
anti-IL-1a antibodies and an IL-1 receptor antagonist (Anakinra) were used to interrogate the potential of IL-1a targeted
therapies in this model. Taken together, these findings identify IL-15 and IL-1a as therapeutic targets in lymphoma.
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Introduction
The Dual Role of IL-15 in Hematopoietic Malignancies
IL-15 is a central cytokine in lymphocyte development,
hematopoietic malignancies, and immunotherapy, where it has
paradoxically been described as both a promoter of cancer and a
promoter of anti-cancer immunity. [1,2] IL-15 belongs to the
family of four-helix-bundle cytokines (also including IL-2, IL-4, IL-
7, IL-9, and IL-21) which use receptors that share a common
gamma-c chain and have unique alpha chains. While there is
partial redundancy among this family of cytokines, IL-15 has
emerged as one particularly suited for antitumor activity. IL-15 is
an important factor in the development, homeostasis, prolifera-
tion, and activity of CD8+ T cells, NK cells, NKT cells, and
intraepithelial T cells. [3] IL-15 also activates monocytes,
macrophages, and dendritic cells; inhibits apoptosis in granulo-
cytes and lymphocytes; promotes a persistent immune response
without inducing Treg activity; and represents a prime candidate
for facilitating innate and durable adaptive tumor immunity. [2].
Although IL-15 is regarded as an excellent candidate for tumor
therapy, it has also been characterized as a promoter of cancer.
Co-discovered in HuT-102 cells transformed by HTLV-1 [4,5],
subsequent studies have confirmed the importance of IL-15 in a
variety of hematopoietic malignancies and solid tumors. The
potential mechanisms by which IL-15 mediates its pro-tumor
activity include protecting tumor cells from apoptosis, and
promoting proliferation, migration, invasion and metastasis.
[6,7] IL-15 is an important mediator of growth, and survival of
the malignant cells in hematopoietic malignancies and solid
tumors. [6,8,9] In fact, overexpression of IL-15 in transgenic mice
is sufficient to cause CD8 leukemia and T-LGL or NKT leukemia.
[10,11] While IL-15 over-expression promotes leukemia/lympho-
ma, it is less well understood if IL-15 is a necessary prerequisite for
cancer development. Similarly, IL-15 has the potential to be a
high-value therapeutic target. What is less clear is whether
systemic modulation of IL-15 activity represses or stimulates
hematopoietic malignancies in vivo.
TAX-LUC Mice as a Model of Human Lymphoma
HTLV-1, the etiologic agent of adult T cell leukemia/
lymphoma (ATL), is a human retrovirus that carries the Tax
oncogene. Tax activates viral transcription through the 59 long
terminal repeat (LTR) but is also capable of constitutively
activating the NFkB pathway in infected cells which results in
overexpression of IL-15. [5,12] As a model of ATL, TAX
transgenic mice, in which Tax expression is governed by the
human granzyme B promoter, develop large granular lymphocytic
lymphoma. [13] The TAX-LUC strain is a second generation
model developed to take advantage of Tax as a strong activator of
viral transcription through the HTLV-1 LTR. [14] A transgene in
which firefly luciferase is driven by the HTLV-1 LTR (LTR-LUC)
was introduced to make double transgenic TAX-LUC mice.
Therefore, in TAX-LUC mice, Tax expression drives both
tumorigenesis and luciferase expression, which can be detected
non-invasively using bioluminescence imaging. Lymphoma in this
model presents as subcutaneous tumors, massive splenomegaly,
involvement of the bone marrow resulting in hypercalcemia and
osteolytic bone lesions, and a chronic inflammatory response
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involving the persistent activation and recruitment of neutrophils
to the tumor. [14,15] Within the tumors, the malignant lymphoma
cells comprise only 10–15% total tumor cells. The majority of the
tumor is populated by infiltrating immune cells, primarily
neutrophils, but also T cells, NK cells, and macrophages. Like
ATL patient samples and cell lines, IL-15 mRNA is expressed in
tumors that arise in TAX-LUC mice along with other NFkB
inducible genes. [16] While IL-15 expression is associated with
Tax tumor initiation and growth, the net effect of IL-15 expression
in vivo has not yet been established.
What is the Net Effect of IL-15 in Tax-lymphoma?
Using Tax-LUC mice as a model in which IL-15 is capable of
promoting both cancer and cancer immunity, we sought to
determine the effect of IL-15 loss on tumor growth in vivo. To this
end an IL-152/2 TAX-LUC strain was developed and examined.
Based on our initial observation that IL-15 overexpression
correlated with tumor growth we hypothesized that loss of IL-15
would impede tumor onset or growth. Surprisingly, IL-15 deficient
TAX-LUC mice developed significantly larger tumors compared
to IL-15+/+ TAX-LUC littermates. Further analysis of these
tumors revealed effects of IL-15 loss on both the malignant
population and the tumor infiltrating immune cells and led us to
conclude that the net effect of IL-15 in this cancer model is
promotion of tumor immunity.
Results
IL-15 is Not Required for Lymphomagenesis
The Tax oncogene in TAX-LUC mice is regulated by the
granzyme B promoter and drives tumorigenesis and transforma-
tion of CD16HI large granular lymphocytes. IL-15 expression is
known to be elevated in these tumors [16] but the role of IL-15
and its effect on the tumor is unclear. To ascertain the function of
IL-15 in Tax lymphoma, we created IL152/2 TAX-LUC mice
and observed that IL-15 is not required for tumor onset or growth.
Instead, mice lacking IL-15 had a slightly accelerated rate of
tumor onset (FIG. 1A) and a significantly increased mortality rate
(FIG. 1B) compared to age-matched IL-15+/+ littermates. IL-15+/
2 littermates had an intermediate phenotype. In the absence of IL-
15, tumors were composed of CD16/32HI large granular
lymphocytes and CD16LO neutrophils (FIG. 1C,G,H), and mice
developed splenomegaly and elevated lymphocyte counts in the
peripheral blood (FIG. 1F) as is typically seen in TAX-LUC mice.
[14] The most distinctive aspects of Tax-tumors were conserved
even in the absence of IL-15 including splenomegaly, osteolytic
bone lesions, a predominant admixture of tumor infiltrating
Ly6G+ neutrophils (FIG. 1D), and constitutive NFkB activity
within the malignant LGLs (FIG. 1E). These data demonstrate
that IL-15 has a dramatic effect on survival but is not required for
Tax-induced tumorigenesis such that neither the type of malig-
nancy, nor the distinctive characteristics of the tumor model were
modified by the absence of IL-15.
IL-15 Represses Tumor Growth
Instead of exposing the cytokine as a necessity for tumor
development, the absence of IL-15 dramatically accelerated tumor
growth (FIG. 2A). Luciferase expression resulting from Tax
activity in the large tumors (FIG. 2B) correlated with the increased
levels of Tax protein and RNA in IL-152/2 tumors (FIG. S1).
Although IL-152/2 tumors were larger, no significant increase in
the overall percentage of malignant cells in these tumors was
observed (FIG. 1C insets). The level of Tax expression per tumor
cell was increased in the absence of IL-15. Myeloperoxidase
activity of tumor infiltrating leukocytes (FIG. 2C) also correlated
with areas or Tax expression. IL-15-deficient mice developed
larger tumors than their IL-15+/+ littermates and produced more
tumors with a faster growth rate (FIG. 2D–F). Moreover,
administration of soluble IL-15 was sufficient to transiently reduce
the rate of tumor growth in IL-152/2 mice (FIG. 2G). The
accelerated rate of tumor growth was not due to a greater
percentage of proliferating cells within the tumor (IL-15+/+=49%
vs. IL-152/2=46%) but was instead associated with a reduced
percentage of tumor cells undergoing apoptosis (37% vs. 12%)
(FIG. 2H, FIG. S2). Taken together these findings establish that
IL-15 represses tumor growth in Tax lymphoma by promoting
tumor cell death.
IL-15 Regulates Tumor Infiltrating Cells and Tumor
Associated Cytokines
To better understand the mechanism by which IL-15 regulates
tumor growth we examined the effect of IL-15 loss on gene
expression within two tumor cell populations, CD16/32HI, which
is highly enriched in Tax+ malignant large granular lymphocytes,
and CD16/32LO, which is a population of tumor infiltrating cells
enriched in neutrophils. [17] Arrays were then performed to
quantify RNA isolated from these tumor cell populations in IL-
15+/+ and IL-152/2 tumors (FIG. 3A). The average results
obtained from two independent tumors of each genotype identified
transcripts that were affected by the absence of IL-15 (FIG. 3B,
FIG. S3). Within the malignant CD16/32HI population, IL-1a
and its receptor IL-1r1, IL-1a-regulated cytokines ccl3 (aka: MIP-
1a) and cxcl3 (aka: MIP-2b,Gro-3), and IL-1 family member 9
were among the transcripts most highly elevated in the absence of
IL-15. On the other hand, ccl8 (aka: MCP-2) and cxcl9 (aka: MIG)
expression was dramatically repressed in the malignant population
in the absence of IL-15.
Surprisingly, these data indicated that IL-15 gene expression
was also elevated in the CD16/32HI cells in IL-152/2 tumors. To
resolve this discrepancy, a more detailed examination was
conducted of the unsummarized data from each of the 26
oligonucleotide probes complementary to the 1.25kb IL-
15 mRNA on the array (FIG. S4). In IL-152/2 mice, a PGK-
Neo cassette replaced exons 3–5 of the 8 exons of IL-15. This
region corresponds to 9 of the 26 probes on the chip. Sequence
complementary to the remaining 17 probes is still present in IL-
152/2 mice and, on average, these 17 remaining probes reveal a
5-fold increase in IL-15 message even though the mRNA does not
produce IL-15 protein. The low signal associated with the 9 probes
complementary to the missing exons reflects the non-specific
background signal of the chip.
Among the population of CD16/32LO tumor infiltrating cells,
transcripts of the neutrophil granule protein arginase 1 were
markedly elevated. Tumor neutrophils in TAX-LUC mice are
frequently hypersegmented with basophilic cytoplasm and ring
forms are also abundant with prominent nucleoli. These
characteristics were also evident in the absence of IL-152/2
(FIG. 1 D,E,G,H). However, platelet clumping and an abundance
of immature neutrophils in the peripheral blood in IL-152/2 mice
was also indicative of an impact of IL-15 loss on involved bone
marrow. Reduction in gene expression in the CD16/32LO
population, not surprisingly, correlated with the reduction in IL-
15 dependent cell lineages. Transcripts found in NK and CD8+
cytotoxic T cells were most reduced in the absence of IL-15
(FIG. 3B). Moreover, the decrease in CD8 cells in IL-152/2
tumors was confirmed by FACS (FIG. S5).
Finally, cytokine arrays were used to examine effects of IL-15
loss at the protein level in whole tumors (FIG. S6). Tumor
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Figure 1. IL-15 is not required for Tax Tumorigenesis. A) Incidence of tumor onset in IL-152/2 TAX-LUC mice (red line, n = 10) compared to IL-
15+/+ TAX-LUC littermate control mice (black line, n = 21), p = 0.03 (2-tailed, paired Student’s T Test). B) Survival curve comparing IL-152/2 TAX-LUC
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homogenates include epithelial, stromal, endothelial and tumor
infiltrating cell types in addition to those analyzed by RNA array.
The most pronounced effect of IL-15 loss on tumor-associated
cytokine protein was on IL-6, which was reduced an average of 7-
fold in IL-152/2 Tax tumors. Since this effect was not seen in the
CD16/32+ populations, IL-15 may be important in regulation of
IL-6 in T cells or other CD16/322 cells in the tumor
microenvironment. It is also noteworthy that, unlike IL-1b, the
elevated levels of IL-1a in normal skin keratinocytes was
sufficiently high in this assay to mask any quantifiable effect of
IL-15 on IL-1a protein expression within the underlying tumor.
Thus, proliferating in the context of significantly reduced numbers
of NK and CD8 cells, the malignant population of CD16/32HI
LGLs within IL-152/2 tumors expressed elevated IL-1a and IL-
1a-regulated transcripts and recruited activated tumor-infiltrating
neutrophils.
Loss of IL-15 Exposes IL-1a as a Regulator of Tumor
Growth and Potential Therapeutic Target
Elevated levels of tumor-cell associated IL-1a protein were
present in formalin-fixed paraffin embedded sections of IL-152/2
tumors (Fig. 4A, Fig. S2). Interestingly, IL-1a abundance in the
skin surrounding the tumor was independent of IL-15. If IL-1a
expression in tumor cells is elevated in the absence of IL-15-
dependent cell-mediated immunity, and it contributes to tumor
cell death in the context of a competent immune system, we asked
if IL-1a could be used as a therapeutic target. Two approaches
were used to interrogate the potential of IL-1a targeted therapies
in this model. In one experiment, neutralizing anti-IL-1a
antibodies were administered to IL-15+/+ TAX-LUC mice and
over the course of treatment, tumor growth was reduced
compared to vehicle (FIG. 4B). Examination of anti-IL-1a treated
tumors upon necropsy revealed an increase in tumor infiltrating
CD4+ and CD8+ T cells and a decrease in the populations of both
malignant LGLs and neutrophils. The antibody-based therapy
could be inhibiting IL-1a signaling and/or may be targeting tumor
cells for antibody dependent cell cytotoxicity (ADCC). To
distinguish between these possibilities, Anakinra, a recombinant
form of the IL-1 receptor antagonist, was administered to tumor
bearing mice to block IL-1 signaling (FIG. 4C). In this experiment,
two distinct responses were observed. Anakinra was tumoristatic in
7 of 9 tumors resulting in elevated percentages of CD4+ and CD8+
T cells and fewer tumor-associated neutrophils. However, in 2 of 9
tumors, Anakinra treatment resulted in accelerated tumor growth,
higher numbers of LGLs, and had no effect on CD4+ T cells or
neutrophils. These data identify IL-1a and IL-1 signaling as
potential therapeutic targets.
Discussion
This study was designed to determine whether IL-15 expression
is a necessary prerequisite for lymphoma development in this
mouse model, and whether systemic modulation of IL-15 activity
is more likely to repress or stimulate similar malignancies in vivo.
In the absence of IL-15, TAX-LUC mice developed larger, more
aggressive tumors that resulted in accelerated mortality. The
increase in tumor growth was transiently reversed in the presence
of soluble IL-15 and the dearth of NK and CD8+ T cells in IL-
152/2 mice is the likely cause of this phenotype. Interestingly,
rapid tumor growth immediately followed the growth inhibitory
effects of soluble IL-15 leaving open the possibility that admin-
istration of IL-15 may simultaneously promote tumor cell growth
and cell mediated tumor immunity in vivo.
While IL-15 was clearly not required for tumor growth in this
model, IL-15 was essential for anti-tumor immunity. Because IL-
15 is required for production of functional NK and CD8+ T cells,
this model was not intended to distinguish between the effects of
functional defects in NK and CD8+ T cells versus lack of
recruitment. Instead, the tumor environment in IL-152/2 mice,
with reduced selective pressure of cellular cytotoxicity, revealed an
unexpected transcriptional profile in the malignant cells that is
apparently masked by tumor immunity. These masked targets
carry potential as biomarkers capable of recruiting or activating an
anti-tumor immune response. This study revealed one such target
in the malignant cells to be IL-1a.
IL-1a and Tumor Immunity
While IL-1a and IL-1b can have similar biological activities in
recombinant or secreted form, these closely related cytokines seem
to play very different roles in tumor immunology. [18] IL-1b is
active only as a secreted product but IL-1a is also active in its cell-
associated forms, as an intracellular precursor or in its membrane
bound forms. Membrane-associated IL-1a can signal in a
juxtracrine manner [19] and is highly immunostimulatory, [20]
capable of activating CTL and NK cells and promoting anti-
tumor immunity and tumor regression. [21–24] In the absence of
cell-mediated immunity both IL-1a and IL-1b promote tumor
growth. [25] However in an immune-competent host, IL-1a
appears to be a key regulator of innate immunosurveillance
mechanisms that promote cell-mediated repression of malignancy.
[24,26] IL-1b, on the other hand, leads to immune suppression of
the host by activation and recruitment of Treg cells and CD11b
+/
Gr1+ immature myeloid cells and it promotes systemic inflamma-
tion, tumor invasiveness and tumor angiogenesis. [21,22,27].
Intracellular IL-1a carries a nuclear localization signal in its N-
terminus and is a chromatin associated cytokine [28] that can
regulate gene expression by binding the p300-PCAF complex and
activating genes in the NFkB and AP-1 pathways. [29,30]
Intracellular IL-1a can also be released during cell necrosis,
where its receptor-interacting C-terminus is capable of recruiting
infiltrating myeloid cells. [28] Under hypoxic conditions, HIF-1a
regulates IL-1-dependent recruitment of myeloid cells [31] such
that IL-1a expression correlates with the infiltration of neutrophils,
whereas IL-1b is associated with the recruitment of macrophages.
[28,32] In sum, IL-1a and IL-1b are unique therapeutic targets
and cell-associated IL-1a is well-suited to serve as a tumor
biomarker, CTL adjuvant, and target for antibody or comple-
ment-mediated cellular cytotoxicity.
mice (red line, n = 13) and IL-15+/2 TAX-LUC mice (blue line, n = 14) to IL-15+/+ TAX-LUC littermate control mice (black line, n = 10). p = 0.006 for KO vs.
WT and p= 0.02 for HET vs. WT. C) Image of CD16/32 immunohistochemistry of IL-152/2 TAX-LUC tumor sections in which the malignant large
granular lymphocytes (red arrows) are stained along with an admixture of tumor infiltrating neutrophils (black arrows). Insets are FACS histograms of
homogenates from IL-15+/+ TAX-LUC or IL-152/2 TAX-LUC tail tumors unstained (white curves) or stained with anti-CD16/32 FITC (red curves). D)
Image of Ly6G immunohistochemistry of IL-152/2 TAX-LUC tumor sections in which tumor infiltrating neutrophils (black arrows) are stained. Insets
are FACS histograms of homogenates from IL-15+/+ TAX-LUC or IL-152/2 TAX-LUC tail tumors unstained (white curves) or stained with anti-Ly6G-PE
(red curves). E) Image of phosho-RelA immunohistochemistry of IL-152/2 TAX-LUC tumor sections in which many of the malignant large granular
lymphocytes (red arrows) show nuclear localization as a marker of NFkB activation. F) Image of a peripheral blood smear (Wright’s stain). G)
Hematoxylin and eosin stained IL-152/2 TAX-LUC tumor section. H) Image of Ki67 immunohistochemistry of IL-152/2 TAX-LUC tumor sections.
doi:10.1371/journal.pone.0085028.g001
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Figure 2. IL-15 represses tumor growth. A) Photograph of tail tumors on an IL-15+/+ TAX-LUC mouse and three IL-152/2 TAX-LUC littermates at
8 mo of age. B,C) Bioluminescent imaging of IL-152/2 TAX-LUC mice to detect Tax activity (using D-luciferin to measure LTR-Luciferase activity), and
neutrophil infiltration (using Luminol to measure myeloperoxidase released from degranulating, tumor-infiltrating neutrophils). D–F) Bar graphs
representing the average tumor growth rate, the average tumor size, and the average number of tail tumors per mouse on IL-15+/+ (n = 5), IL-152/2
(n = 10) TAX-LUC mice. Weekly, bi-directional caliper measurements were taken for each tumor from tumor onset to death. Tumor volume doubling
time was calculated for each tumor. To determine the growth rate, the average doubling time for IL-15+/+ TAX-LUC mice was set to 1 to obtain the
relative average doubling time of IL-152/2 TAX-LUC mice. Tumor size is shown as tumor volume in mm3. Number of tail tumors was calculated at 9
months of age. Error bars indicate the standard deviation and p values show 2-tailed, paired Student’s T Tests. G) The effect of murine IL-15 on tumor
growth. IL-152/2 TAX-LUC mice received saline (black curve, n = 3) or mIL-15 (red curve, n = 5) at times indicated by red arrows. Error bars represent
standard deviation of average tumor volume as measured by calipers. H) Images of representative immunohistochemistry stains for proliferation
(proliferating cell nuclear antigen; PCNA) and apoptosis (TUNEL) on IL-15+/+ TAX-LUC and IL-152/2 TAX-LUC tail tumor sections.
doi:10.1371/journal.pone.0085028.g002
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Figure 3. IL-15 regulates tumor infiltrating cells and tumor associated cytokines. A) Schematic representation of experimental design. RNA
harvested from CD16/32HI and CD16/32LO cells from IL-15+/+ and IL-152/2 TAX-LUC tail tumors were analyzed by array. B) Profiles of gene expression
changes associated with the absence of IL-15 in CD16/32HI and CD16/32LO tumor cell populations.
doi:10.1371/journal.pone.0085028.g003
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IL-1a and HTLV Tax
Two striking characteristics of ATLL are the long period of
latency that usually precedes disease onset and the low penetrance
of ATL among infected carriers. Among the mechanisms thought
to underlie these characteristics, one major factor is the role of
CTL and host immunity. [33,34] It has been established that the
Tax oncogene is an antigenic target of the adaptive immune
response in HTLV-1 infected individuals. [35] Tax is also known
to activate the IL-1a promoter, [36] several mouse models have
demonstrated elevated levels of IL-1a in response to Tax
expression, [13,17,37] and HTLV-1+ T cell clones produce high
levels of IL-1a in culture. [38] Interestingly, Tax expression is
largely restricted or absent in primary ATL cells [39,40] and the
same is true for IL-1a. [41] Compared to IL-1b, IL-1a is also less
abundant in primary tissue samples of other human malignancies
including melanoma, colon carcinoma, and non-small cell lung
carcinoma. [42] These data are consistent with the hypothesis that
there is a selection against IL-1a expression in ATL cells, and
other malignancies, in vivo. Our data provides a mechanistic
explanation for these observations in ATL. Tax activity leads to
IL-1a expression which recruits and activates cell-mediated killing
of IL-1a -expressing, HTLV-1 infected cells. This is corroborated
by the fact that depletion of IL-1a in a Tax transgenic mouse
model reduced Tax-induced autoimmunity. [43] What remains to
Figure 4. Loss of IL-15 exposes IL-1a as a regulator of tumor growth and potential therapeutic target. A) Images of IL-1a IHC in IL-15+/+
(middle) and IL-152/2 (right) TAX-LUC tumor sections compared to control lacking primary IL-1a antibody (left). B) The effect of anti-IL-1a antibodies
(red curve, n = 5) on tumor growth compared to saline (black curve, n = 5) in IL-15+/+ TAX-LUC mice over the course of 1 week. Error bars represent
standard deviation of tumor growth, and p values represent 2-tailed, paired Student’s T Tests. The bar graph (right) represents FACS data obtained
from anti-IL-1a treated tumors (red bars) or control tumors (black bars) at necropsy showing the abundance of CD8+, CD4+, CD16/32HI, and CD16/
32LO cells present in the tumor at the experimental endpoint. Y axis is log scale and error bars represent standard deviation. C) The effect of Anakinra
on tumor growth compared to saline. In 7 of 9 mice Anakinra resulted in repression of tumor growth (Anakinra R, red line), while in 2 of 9 mice
Anakinra resulted in promotion of tumor growth (Anakinra P, blue line). Graph is double-Y to accommodate the scale differences between Anakinra R
and control (left scale) versus Anakinra P (right scale). Red arrows indicate the time points of daily Anakinra injections, error bars represent standard
deviations and p values represent 2-tailed, paired Student’s T Tests. The bar graph (right) represents FACS data obtained from Anakinra treated
tumors or control tumors at necropsy showing the abundance of CD8+, CD4+, CD16/32HI, and CD16/32LO cells present in the tumor at the
experimental endpoint. Y axis is log scale and error bars represent standard deviation.
doi:10.1371/journal.pone.0085028.g004
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be determined is whether IL-1a-directed therapies can enhance
killing of HTLV infected cells in vivo, reduce viral load, or target
Tax-dependent mechanisms of ATL progression.
Translational Implications of IL-15 and IL-1a
IL-15 is already recognized as a promising candidate for tumor
immunotherapy. [1,2] The principle findings in this study are that
IL-15 is critical in the inhibition of tumor growth in this model and
that IL-1a expression is targeted by IL-15-dependent anti-tumor
activity (FIG. 5). Taken together these findings provide a rationale
for testing IL-15, an anti-IL-1a antibody or a combination of both
in lymphoma. The combination of IL-15 and cetuximab increased
ADCC activity against triple negative breast cancer cell lines and
enhanced cetuximab efficacy against HER1-positive head and
neck cancer. [44,45] IL-15 has also been shown to enhance
rituximab-dependent cytotoxicity against chronic lymphocytic
leukemia cells. [46] Moreover, the combination of IL-15 and
anti-CD40 is more efficacious than either therapy alone in mouse
models of metastatic colon cancer or metastatic renal cell
carcinoma. [47–49] An anti- IL-1a monoclonal antibody
(MABp1, Xbiotech) is currently undergoing clinical trials for
treatment of advanced leukemia and other cancers, and has shown
evidence of anti-tumor activity. [50] Alone and in combination,




IL-152/2 mice on a C57BL/6 background (3, Taconic) were
intercrossed with TAX-LUC transgenic mice on a C57BL/
66FVB background. [14] The use of murine models and tissues in
this study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Mice
were housed under pathogen-free conditions according to the
guidelines of the Division of Comparative Medicine and all
experiments were approved by the Animal Studies Committee,
Washington University School of Medicine under ASC protocol
#20100026.
Histology and Immunohistochemistry
Tumor or organ tissue was fixed in 10% buffered formalin and
paraffin-embedded sections were processed for immunohisto-
chemical stains. Slides were heated to 55oC for 10 minutes,
deparaffinized in xylene, and rehydrated in deionized water. For
antigen retrieval/unmasking, slides were boiled (under pressure) in
citric acid buffer (pH 6) for 15 minutes and allowed to cool to
room temperature. In some cases, slides were also treated with
proteinase K (20 ug/mL in TE, pH 8) for 2 minutes at room
temperature, and washed with PBS. Endogenous peroxidase
activity was blocked by incubating the slides in 0.3% hydrogen
peroxide solution for 5 minutes. For Ki67 staining, slides were
then blocked in normal equine serum (Jackson ImmunoResearch
Laboratories Inc.) for 15 minutes and rinsed. Slides were soaked in
rabbit polyclonal anti-Ki67 (Vector Laboratories) overnight at
4uC. Slides were then washed and incubated in ImmPRESS
reagent anti-rabbit IgG (Vector Laboratories) for 30 minutes at
room temperature, incubated in DAB peroxidase substrate, rinsed,
and coverslipped. TUNEL (terminal deoxynucleotidyl transferase
dUTP nick end labeling) staining was conducted according to
manufacturer’s protocol (Trevigen). For CD16/32 staining addi-
tional blocking steps with avidin D solution (Vector Laboratories)
and for 15 min at room temp, followed by biotin for 15 minutes at
room temperature was included prior to incubation in primary
biotin rat anti-mouse CD16/32 antibody (BD Pharmingen)
overnight at 4uC. Rabbit polyclonal anti-PCNA (abcam), rabbit
monoclonal anti-phosphoRel-A (Cell Signaling Technology Inc),
rat anti-mouse Ly6G (eBioscience), and goat polyclonal anti-rat
IL-1a (Santa Cruz biotechnology, Inc) primary antibodies were
used. Negative controls lacking primary antibody were included
for each stain. Sections were visualized with a Nikon Eclipse E400
microscope and digital images were obtained using a Magnafire
camera and software (Optronics).
Treatment Regimens
Soluble mIL-15: IL-152/2 TAX-LUC mice received sub-
cutaneous injections of saline or 100 ng of recombinant mouse IL-
15 (MACS Miltenyi Biotech), 3 times per week every other week
for 5 weeks. Bi-directional caliper measurements of tumors were
taken three times per week for 2 months. Anti-IL-1a antibody: IL-
15+/+ TAX-LUC mice received injections of 50 ug LEAF-
purified, anti-mouse IL-1a antibody (BioLegend) or saline i.p.
every other day for one week and tumors were measured with
calipers. Anakinra: IL-15+/+ TAX-LUC received daily i.p.
injections of 30 mg Anakinra (Swedish Orphan Biovitrum AB)
or saline. Tumors were measured for 35 days prior to treatment
and 15 days after treatment with calipers.
Bioluminescent Imaging
The IVIS100 system (Xenogen) was used to image biolumines-
cence in anesthetized mice (isoflurane inhalation). Standard
imaging parameters included D-luciferin dose 50 mg i.p; luminol
dose 200 mg/kg i.p; exposure 300 sec; binning 4; f/stop 1; no
optical filter. Color scale unless otherwise indicated is 6104
photons/sec/cm2/sr.
Figure 5. Model. A schematic representation of the principle
conclusions; IL-15 is not required for tumor growth but is required for
tumor immunity, IL-1a is more abundant and tumor growth is
accelerated in the absence of IL-15, and therapies that target IL-1
and/or promote cell-mediated tumor immunity should be explored in
lymphoma or other malignancies.
doi:10.1371/journal.pone.0085028.g005
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Flow Cytometry
Cell suspensions derived from organs or tumor homogenates
from IL-152/2 or IL-15+/+ mice were blocked with mouse BD Fc
Block (Rat anti-mouse CD16/32; BD Pharmingen) for 10 minutes
and stained with anti-CD16/32-FITC, anti-CD4-APC, anti-CD8-
PE, and anti-Ly6G-PE antibodies (eBioscience) for 30 minutes at
4uC, washed, filtered and analyzed on a BD FACSCalibur (Becton
Dickinson).
RNA Array
Tail tumors were excised from two IL-152/2 TAX-LUC mice
and two IL-15+/+ TAX-LUC mice. Single cell suspensions were
made, counted, re-suspended in PBS+1%BSA, blocked with Fc
block, stained with anti-CD16/32 for 30 min at 4uC, and sorted
using Sony iCyt Reflection Cell Sorter. Total RNA was harvested
from CD16HI and CD16LO tumor cell populations using
RNAeasy (Qiagen), quantified by spectrophotometry, and sub-
mitted for array analysis (Affymetrix Gene Chip, Whole Tran-
script 1.0ST). Averaged signal intensities for each probe set were
analyzed (Partek) comparing CD16/32HI from each genotype and
CD16/32LO sets from each genotype by 1-way ANOVA and then
filtered for expression changes .3-fold. Original data files are
available (GEO accession # GSE46072).
Protein Array
Tail tumors and normal tail tissue from IL-152/2 and IL-15+/+
TAX-LUC mice were excised and homogenized in PBS with
protease inhibitors (10 mg/mL Aprotinin, 10 mg/mL Leupeptin,
and 10 mg/mL Pepstatin) and Triton X-100 was added to a final
concentration of 1%. Samples were then frozen at 280uC,
thawed, centrifuged at 10,0006g for 5 minutes to remove cellular
debris, quantified, and analyzed using a Proteome Profiler Mouse
Cytokine Antibody Array (R&D Systems) according to manufac-
turer’s instructions.
RT-PCR
2 mg of RNA obtained from sorted cells was subjected to DNase
I digestion (Invitrogen) and RT-PCR was carried out using
SuperScript III First-Strand Synthesis system (Invitrogen) accord-
ing to manufacturer’s instructions. 100 ng of cDNA template was
used for each reaction. Qualitative RT-PCR was performed using
a two-phase, step-down PCR method; 16 cycles of 94uC for 30 s,
64uC (20.5uC/cycle) for 30 s, 72uC for 30 s, followed by 10 cycles
of 94uC for 30 s, 56uC for 30 s, 72uC for 30.
Western Blot
Tumor cells harvested from IL-152/2 and IL-15+/+ TAX-LUC
mice were centrifuged, rinsed, resuspended in RIPA buffer,
sonicated, boiled in SDS buffer for 15 min, and run on 15%
SDS-PAGE at 4uC. Blots were probed using a rabbit anti-Tax
primary antibody.
Supporting Information
Figure S1 Tax Expression. RNA and protein obtained from
tumor cells harvested from IL-152/2 and IL-15+/+ TAX-LUC
mice was used to detect Tax RNA by RT-PCR and Tax protein
by Western Blot normalized against GAPDH and actin loading
controls respectively.
(TIF)
Figure S2 TUNEL, PCNA, and IL-1a IHC in IL-15+/+ and
IL-152/2 tumors. Images of representative immunohistochem-
istry (IHC) stains for apoptosis (Terminal deoxynucleotidyl
transferase dUTP nick end labeling; TUNEL), proliferation
(proliferating cell nuclear antigen; PCNA) and interleukin-1 alpha
(IL-1a) on IL-15+/+ TAX-LUC (top row) and IL-152/2 TAX-
LUC (bottom row) tail tumor sections.
(TIF)
Figure S3 RT-PCR confirmation of selected differen-
tially expressed mRNAs. RNA was obtained from CD16/
32HI and CD16/32LO sorted tumor cells harvested from IL-152/2
and IL-15+/+ TAX-LUC mice.
(TIF)
Figure S4 IL-15 mRNA is elevated in the malignant
CD16/32HI cells in IL-152/2 Tax tumors. A) Raw
(‘‘unsummarized’’) data from each of the 26 oligonucleotide
probes complementary to the 1.25 kb IL-15 mRNA on the array.
Red bars and black bars represent data obtained from CD16/32HI
cells from tail tumors arising in IL-152/2 and IL-15+/+ TAX-
LUC mice respectively. B) Alignment showing the locations of
each of the 26 oligonucleotide probes relative to the exon locations
in the mRNA. In IL-152/2 mice the PGK Neo cassette replaces
exons 3–5 of the IL-15 mRNA which corresponds to probes 7–15
in the array. Probes 7–15 in the IL-152/2 tumors constitute the
background of the array and average a 1.54 fold decrease vs. IL-
15+/+ compared to the 5.26 fold increase in the average of the
remaining probes.
(TIF)
Figure S5 Tumor infiltrating CD8+ cells are reduced in
IL-152/2 Tax tumors. Dot plot histograms of CD4+ (Y-axis)
and CD8+ (X-axis) cells present in tumor homogenates from IL-
15+/+ and IL-152/2 Tax tumors.
(TIF)
Figure S6 Cytokines elevated in Tax Tumors in the
presence and absence of IL-15. Lysates were obtained from
normal tail tissue and whole tail tumors from IL-152/2 and IL-
15+/+ mice and analyzed using the mouse Proteome Profiler.
Representative images are shown from one array next to
densitometry analysis averaging the results of n= 5 IL-152/2
arrays. Densitometry value in normal IL-152/2 tail tissue is shown
and set to 1. A 7-fold decrease in IL-6 protein was consistently
detected in IL-152/2 tumors compared to IL-15+/+ tumors.
(TIF)
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